NCT07178912 2026-05-05Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)M.D. Anderson Cancer CenterPhase 2 Not yet recruiting60 enrolled